Denali Therapeutics Profile

Performance

Odds of Distress

Analyze Filter    Fiscal Quarter End: December 31, 2019
Equity ratings for Denali Therapeutics are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 10, 2019 and ending today December 9, 2019. Click here to learn more.

Denali Therapeutics Profile

Next fiscal quarter end is expected on December 31, 2019. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 255 people. more
Denali Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Denali Therapeutics SEC Filings
Denali Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameDenali Therapeutics
CEORyan WattsView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
LocationCalifornia; U.S.A
Business Address161 Oyster Point Boulevard
ExchangeBATS Exchange
CUSIP24823R105
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.denalitherapeutics.com
Phone650 866 8548
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestNovember 15, 2019
Denali Therapeutics (DNLI) is traded on BATS Exchange in USA. It is located in 161 Oyster Point Boulevard and employs 255 people. Denali Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.73 B. Denali Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 95.84 M outstanding shares of which 9.67 M shares are currently shorted by private and institutional investors with about 27.68 trading days to cover. The company currently holds about 478.6 M in cash with (15.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99.
Check Denali Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Denali Therapeutics Target Price Odds Analysis

Odds Below 18.26HorizonTargetOdds Above 18.26
88.81%30 days 18.26 11.11%
Based on normal probability distribution, the odds of Denali Therapeutics to move above current price in 30 days from now is about 11.11 (This Denali Therapeutics probability density function shows the probability of Denali Therapeutics Stock to fall within a particular range of prices over 30 days) .

Denali Therapeutics Top Holders

Denali Therapeutics Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Crestline Management LpCommon Shares19.5 M298.2 M
Flagship Pioneering IncCommon SharesM122.6 M
View Denali Therapeutics Diagnostics

Denali Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Denali Therapeutics Key Fundamentals

Denali Therapeutics Against Markets

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Denali Therapeutics Upcoming and Recent Events

Denali Therapeutics Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportMarch 10, 2020
Next Earnings ReportMay 13, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndMarch 10, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Denali Therapeutics Corporate Filings

Denali Therapeutics SEC Reporting

Financial Statements and Exhibits. Results of Operations and Financial Condition
Submission of Matters to a Vote of Security Holders
Unclassified Corporate Event
Other Events

Denali Therapeutics Corporate Directors

David Schenkein Independent Director
Peter Klein Independent Director
Douglas Cole Independent Director
Additionally see Investing Opportunities. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Search macroaxis.com